Pier Andrea Borea

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 5 EPO patents, primarily in Receptor Modulators. Top assignees: King Pharmaceuticals Research and Development, Inc., Pharmeste S.r.l., King Pharmaceuticals Reseach and Development, Inc.. Active years: 2001-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pier Andrea Borea. Retrieved from https://idiyas.com/inventor/pier-andrea-borea

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 22.2

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 93(Granted Patents)

Company Filing History:

9 out of 23

King Pharmaceuticals Research and Development, Inc.

King Pharmaceuticals Reseach and Development, Inc.

patent

4. 1 out of 1

King Pharmaceuticuals Research & Development, Inc.

patent

5. 1 out of 1

King Pharmacueticals Reserch and Development, Inc.

Years Active: 2001-2012

Loading Chart...

Areas of Expertise:

Vanilloid Receptor

TRPV1 Antagonists

Adenosine A2B

Adenosine A3

P2X7 Modulators

Biarylcarboxyarylamides

Sulfonamido Compounds

Tumor Growth Inhibition

Pharmaceutically Active Compounds

Tyrosyl Derivatives

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8222275 - Biarylcarboxyarylamides as vanilloid-1 receptor modulators (2012-07-17),

2. 7964642 - Vanilloid TRPV1 receptor antagonists (2011-06-21),

3. 7919624 - VR1 vanilloid receptor antagonists with a iononic substructure (2011-04-05),

4. 7767685 - Adenosine A2B receptor antagonists (2010-08-03),

5. 7750049 - O-substituted-dibenzyl urea-derivatives as TRPV1 receptor antagonists (2010-07-06),

6. 7691825 - [object Object] (2010-04-06),

7. 7579378 - Sulfonamido compounds that antagonize the vanilloid TRPV1 receptor (2009-08-25),

8. 7511133 - [object Object] (2009-03-31),

9. 7470698 - Adenosine A3 receptor modulators (2008-12-30),

10. 7435740 - [object Object] (2008-10-14),

11. 7335655 - [object Object] (2008-02-26),

12. 7271171 - [object Object] (2007-09-18),

13. 7205403 - [object Object] (2007-04-17),

14. 7094895 - Tyrosyl derivatives and their use as P2X7 receptor modulators (2006-08-22),

15. 7064204 - Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use (2006-06-20),

Title: Pier Andrea Borea: Innovator in Pharmaceutical Chemistry

Introduction

Pier Andrea Borea is a notable inventor based in Ferrara, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target the vanilloid-1 receptor. With a total of 18 patents to his name, Borea's work has implications for the treatment of various inflammatory diseases.

Latest Patents

Among his latest patents, Borea has developed biarylcarboxyarylamides as vanilloid-1 receptor modulators. This invention provides compounds of formula (I), wherein A and Z are defined in the description. These compounds are designed for the treatment of inflammatory diseases, including neuropathic pain. Another significant patent involves vanilloid TRPV1 receptor antagonists, which relates to compounds of formula (I) as well. These compounds are intended for use in pharmaceutical compositions aimed at treating inflammatory states.

Career Highlights

Borea has worked with prominent companies in the pharmaceutical industry, including King Pharmaceuticals Research and Development, Inc. and Pharmeste S.r.l. His expertise in the field has allowed him to contribute to innovative solutions in drug development.

Collaborations

Throughout his career, Borea has collaborated with esteemed colleagues such as Pier Giovanni Baraldi and Pierangelo Geppetti. These partnerships have further enhanced his research and development efforts.

Conclusion

Pier Andrea Borea's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a leading inventor in the field. His work continues to influence the development of treatments for inflammatory diseases.

Profile summary based on public USPTO records.